Paratek Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRTK research report →
Companyparatekpharma.com
Paratek Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.
- CEO
- Evan Loh FACC, FAHA,
- IPO
- 2009
- Employees
- 268
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $127.83M
- P/E
- -1.91
- P/S
- 0.85
- P/B
- -0.71
- EV/EBITDA
- -7.84
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 84.71%
- Op Margin
- -30.65%
- Net Margin
- -42.16%
- ROE
- 42.54%
- ROIC
- -34.19%
Growth & Income
- Revenue
- $150.79M · 24.67%
- Net Income
- $-63,566,000 · -7.59%
- EPS
- $-1.17 · 4.10%
- Op Income
- $-46,209,000
- FCF YoY
- -36.04%
Performance & Tape
- 52W High
- $3.65
- 52W Low
- $1.29
- 50D MA
- $2.20
- 200D MA
- $2.06
- Beta
- 1.70
- Avg Volume
- 599.68K
Get TickerSpark's AI analysis on PRTK
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 21, 23 | Baylor-Henry Minnie | sell | 32,800 |
| Sep 21, 23 | Baylor-Henry Minnie | sell | 12,800 |
| Sep 21, 23 | Baylor-Henry Minnie | sell | 26,400 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 64,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 7,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 12,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 5,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 10,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 20,000 |
| Sep 21, 23 | Hoffmann Rolf K | sell | 7,000 |
Our PRTK Coverage
We haven't published any research on PRTK yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PRTK Report →